Company news
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news
Every Agios Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
July 21, 2026
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
July 7, 2026
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
June 29, 2026
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell...
June 13, 2026
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
June 1, 2026
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
May 29, 2026
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
May 22, 2026
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
May 22, 2026
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
May 12, 2026
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
May 12, 2026
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
April 29, 2026
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
April 6, 2026
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
March 31, 2026
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
March 2, 2026
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 12, 2026
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
January 26, 2026
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
January 12, 2026
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
January 5, 2026
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
December 23, 2025
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
December 8, 2025
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
November 19, 2025
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
November 3, 2025
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
October 30, 2025
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
October 17, 2025
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
October 16, 2025
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
September 4, 2025
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
August 4, 2025
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
July 31, 2025
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
July 14, 2025
Agios Appoints Dr. Jay Backstrom to Board of Directors
July 8, 2025
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
May 28, 2025
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
May 14, 2025
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
May 9, 2025
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
May 2, 2025
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 1, 2025
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
April 17, 2025
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
March 5, 2025
Agios to Present at Upcoming Investor Conferences
March 4, 2025
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
February 20, 2025
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary End...
February 13, 2025
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 13, 2025
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
February 6, 2025
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
January 13, 2025
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Trans...
January 8, 2025
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
January 8, 2025
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
January 3, 2025
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
December 18, 2024
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
December 8, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
November 5, 2024